LumiThera is a Seattle-based commercial-stage medical device company developing the Valeda Light Delivery System, a multi-wavelength photobiomodulation (PBM) treatment for ocular disorders including dry age-related macular degeneration (AMD) and diabetic retinopathy. The company has been granted CE Mark authorization for Valeda in the European Economic Area, but Valeda is not approved by the U.S. Food & Drug Administration. LumiThera is completing enrollment in two prospective, randomized, double-masked clinical trials: LIGHTSITE II in Europe and LIGHTSITE III in the U.S., and is planning additional trials for diabetic macular edema and AMD. It raised approximately $14M in a Series C financing. The company intends to use the proceeds to commercialize Valeda, complete LIGHTSITE III enrollment, and pursue U.S. regulatory clearance. Led by President and CEO Clark Tedford, Ph.D., LumiThera focuses on office-based PBM treatments delivered by eye care specialists. LumiThera is a Seattle-based clinical-stage medical device company developing non-invasive photobiomodulation (PBM) treatments for ocular disorders using light-emitting diodes. Its lead product is the LT-300, an ophthalmologist LED office-based instrument being developed to treat dry age-related macular degeneration (AMD). The company is conducting the LIGHTSITE I study, a prospective, randomized, double-masked clinical trial in 30 dry AMD subjects using the LT-300 light delivery system. LumiThera plans to use recently raised funds to further develop the LT-300, pursue regulatory clearances in select countries outside the USA including the CE mark in Europe, and expand clinical and commercial activities. The company completed a $5.5M Series B round led by WaterStone Capital with participation from RPR Venture. Clark Tedford, Ph.D., serves as President and CEO.

Total raised

$20M

Funding rounds

2

Latest round

Series C

Latest activity

Jul 2020